ReviewExpert opinion on biological therapy2008
Biofunctionalized targeted nanoparticles for therapeutic applications.
Review in Expert opinion on biological therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed.
- Nanoparticle based siRNA therapeutics for ovarian cancer overcoming drug resistance and future directions.Discover nano · 2026Review
- Magnetic nanoparticles for cancer theranostics.Biomedical physics & engineering express · 2026Review
- Targeted delivery of peptide functionalized nanoparticles for ameliorating myocardial infarction.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Review
- Advancements in Bio-Nanotechnology: Green Synthesis and Emerging Applications of Bio-Nanoparticles.Nanomaterials (Basel, Switzerland) · 2025Review
- Combined Esculentin-2CHa Fusion Protein-Coated Au Nanoparticles for Effective Against Non-Alcoholic Fatty Liver Disease in Mice Model.International journal of nanomedicine · 2025Article
- The Use of Lipid-based Nanocarriers to Improve Ovarian Cancer Treatment: An Overview of Recent Developments.Current pharmaceutical biotechnology · 2024Review
- Conversion of Chemical Drugs into Targeting Ligands on RNA Nanoparticles and Assessing Payload Stoichiometry for Optimal Biodistribution in Cancer Treatment.RNA nanomed · 2024Article
- Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery.International journal of nanomedicine · 2024Review
- Article
- Advances in lipid-based carriers for cancer therapeutics: Liposomes, exosomes and hybrid exosomes.Cancer letters · 2023Article
- Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin - A review.Inorganic chemistry communications · 2023Review
- Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Generation of peptides using phage display technology for cancer diagnosis and molecular imaging.Molecular biology reports · 2023Review
- Modulating the Surface Properties of Lithium Niobate Nanoparticles by Multifunctional Coatings Using Water-in-Oil Microemulsions.Nanomaterials (Basel, Switzerland) · 2023Article
- Functionalized Nanogels with Endothelin-1 and Bradykinin Receptor Antagonist Peptides Decrease Inflammatory and Cartilage Degradation Markers of Osteoarthritis in a Horse Organoid Model of Cartilage.International journal of molecular sciences · 2022Article
- Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Targeted Nanocarrier Delivery of RNA Therapeutics to Control HIV Infection.Pharmaceutics · 2022Review
- Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics.Nanomedicine (London, England) · 2021Review
- Harnessing nanotechnology to expand the toolbox of chemical biology.Nature chemical biology · 2021Review
- Nanostructured Polymeric, Liposomal and Other Materials to Control the Drug Delivery for Cardiovascular Diseases.Pharmaceutics · 2020Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe development of nanoparticles for the delivery of therapeutic agents has introduced new opportunities for the improvement of medical treatment. Recent efforts have focused on developing targeted nanoparticles, which are formulated by (for therapeutic delivery) functionalizing nanoparticle surfaces with targeting molecules, such as antibodies, peptides, small molecules and oligonucleotides.
objectivesTo review the state of targeted nanoparticles development.
methodsThe authors discuss the nanoparticle platforms for therapeutic delivery, targeting molecules and the biofunctionalized targeted nanoparticles currently in development. RESULTS/
conclusionsBiofunctionalized targeted nanoparticles have demonstrated exciting results in preclinical studies. With continued improvements, they may fulfill their potential as therapeutics carriers that can deliver the maximum dose to diseased tissue while minimizing effects on normal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.